X-linked Hypophosphatemia (XLH)
0
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Alder TherapeuticsSweden - Solna
1 programEffective Dosing of Burosumab in XLHN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2025
2026
Alder TherapeuticsEffective Dosing of Burosumab in XLH
Clinical Trials (1)
Total enrollment: 120 patients across 1 trials
Effective Dosing of Burosumab in XLH
Start: Sep 2025Est. completion: Jan 2026120 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 120 patients
1 companies competing in this space